Fellow Investor,
If you’re looking for a way to make money in the markets without investing in volatile AI stocks…
Or plunking your hard-earned money into complicated crypto currencies…
Then you’re going to love my e-book called “How To Master The Retirement Trade.”
Because it reveals how to use a little-know strategy I’ve developed to pinpoint – and profit – from trades that can play out in as little as 11 hours.
You can reserve your copy here now….
Just be sure to do it now.
To prevent the trades I release from getting overcrowded with profit-hungry investors…
I’m strictly limiting the number of people who get copies of this guide.
To your investing success,
Dave Aquino
Partner, Head of Options Trading
Base Camp Trading
Why Congress Is Buying Intuitive Surgical Ahead of Earnings
Written by Gabriel Osorio-Mazilli. Published 10/14/2025.
Key Points
- Intuitive Surgical has attracted recent congressional buying ahead of its next quarterly earnings results, implying a new potential bull run.
- The FDA cleared the business to continue offering new products, expanding its financial stance.
- Analysts still call for double-digit upside from today's discounted prices.
Intuitive Surgical Inc. (NASDAQ: ISRG) is entering a potential breakout window as it heads into its next earnings report on October 21, 2025. A string of recent developments has improved the outlook and set the stage for a possible rally leading into—or following—the announcement.
With new FDA approvals and regulatory clearance for European expansion, Intuitive Surgical now has access to a much larger, more actionable customer base. Those developments have meaningfully expanded its addressable market and could drive increased adoption of its systems across the United States and abroad.
NEW LAW: Congress Approves Setup For Digital Dollar? (Ad)
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0
But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."
That broader reach should begin to show up in improved earnings over the coming quarters. As is often the case in the healthcare sector, regulatory shifts play a pivotal role in shaping investor sentiment.
Notably, there's growing speculation that key regulations could soon clear, especially given recent buying activity from several U.S. Congress members—a signal that hasn't gone unnoticed by the market. As a result, investors are applying a premium valuation to the company, reflecting heightened expectations for future growth. For retail investors, this is an opportunity worth considering.
Why Intuitive Surgical Can Win
Intuitive Surgical develops AI-driven robotics for surgical procedures, enabling medical professionals to perform complex procedures with greater precision. The company benefits from wide competitive moats—high switching costs, a strong installed base and specialized software—that are hard for rivals to breach even as AI becomes more prevalent.
One key catalyst is the recent FDA approval for da Vinci 5 software features, which should facilitate broader adoption and enable more robotics- and AI-assisted procedures.
Another driver is the progress of the Ion endoluminal system trials, which have been cleared across Europe and the United States and involve more than 2,000 subjects. Those studies increase the likelihood that the company will report more diversified and faster-growing revenue streams, supporting a higher valuation.
Despite these bullish factors, the stock currently trades at roughly 70% of its 52-week high, creating a more attractive risk-to-reward ratio for new and existing shareholders. Some of the recent buyers include congressional members, who may have insight into upcoming regulatory developments.
Markwayne Mullin bought up to $100,000 at an average price of $443.99 per share, and Ro Khanna bought up to $15,000 at an average of $466.66. These purchases were made in September 2025, about a month before the company's quarterly results; given the recent FDA approvals and European expansion, some investors expect positive guidance.
What Markets Think of Intuitive Surgical Stock
A straightforward way to gauge sentiment is through valuation multiples. Intuitive Surgical's price-to-earnings ratio of 59.9x indicates investors are willing to pay a substantial premium. By comparison, the medical instruments industry trades at about 26.3x, which helps explain why markets are assigning a higher multiple to ISRG.
The Wall Street analyst consensus price target on the stock is $589.43 per share, implying roughly 37.2% upside from its current trading price, not accounting for potential financial benefits from recent developments.
In its latest quarter the company reported earnings per share (EPS) of $2.19, about 13% above the MarketBeat consensus of $1.93. That beat supports the fundamental case, but the trade also benefits from broader market dynamics.
The Healthcare Select Sector SPDR Fund (NYSEARCA: XLV) has underperformed the S&P 500 by roughly 22% over the past 12 months, the widest gap in over a decade. That compression has left healthcare valuations and price action relatively depressed.
If a recovery extends across the sector, Intuitive Surgical—given its strong fundamentals—could participate in an accelerated rally alongside its peers, creating an attractive risk-to-reward setup for investors.
This email content is a sponsored email provided by Base Camp Trading, a third-party advertiser of MarketBeat. Why did I get this email message?.
This promotional message is sent on behalf of Base Camp Trading, located at 5540 Centerview Drive, Suite 204, Raleigh, NC 27606. If you no longer wish to receive promotional emails from Base Camp Trading, please unsubscribe here with the "optout" in the subject line.
If you have questions or concerns about your newsletter, please contact MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2025 MarketBeat Media, LLC. All rights protected.
345 N Reid Place #620, Sioux Falls, South Dakota 57103-7078. United States..
Post a Comment
Post a Comment